- Anteris Technologies (AVR) reports marked improvements since the three-month follow-up of its first cohort of five patients who have the DurAVR heart valve replacement
- The company says all patients are doing “very well”, with key data showing an 86 per cent reduction in haemodynamics since baseline
- Further, the six-minute walk test, a key marker of patient well-being, shows a 46 per cent improvement since baseline and a further 21 per cent improvement between three and six months
- Shares in Anteris are up 10.1 per cent, trading at $23 at market close
Meditech specialist Anteris Technologies (AVR) has reported marked improvements since the three-month follow-up of its first cohort of five patients who have the DurAVR heart valve replacement.
The company said all patients are doing “very well”, with key data showing an 86 per cent reduction in haemodynamics since baseline.
Further, the six-minute walk test, a key marker of patient well-being, has improved 46 per cent since baseline and a further 21 per cent improvement between three and six months.
The walk test demonstrates how much more active and fit these patients are able to become.
Chief Medical Officer Chris Meduri said the company continues to see encouraging results in their first group of patients.
“DurAVR demonstrates sustained excellent haemodynamics which results in dramatic improvements in patients’ ability to exercise etc,” he said.
“With an additional eight patients having been implanted recently our data and knowledge continues to expand demonstrating that DurAVR will hold an important role in the future treatment of aortic stenosis.”
Additionally, laminar flow on MRI continues to show significant improvements when compared to existing valves, which is expected to bring significant clinical and patient benefits in the future.
CEO Wayne Paterson echoed Mr Meduri, adding his confidence that Anteris will be a significant player in the aortic stenosis market in the years ahead.
Shares in Anteris were up 10.1 per cent, trading at $23 at market close.